Baird analyst Joel Beatty lowered the firm’s price target on PTC Therapeutics (PTCT) to $70 from $72 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results where management gave encouraging commentary on PKU launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $56 from $52 at TD Cowen
- PTC Therapeutics price target raised to $63 from $60 at RBC Capital
- PTC Therapeutics price target raised to $79 from $78 at Wells Fargo
- PTC Therapeutics Reports Q2 2025 Financial Results
- PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions